Collagenase Clostridium Histolyticum

Introduction Overview

Generic Name

collagenase clostridium histolyticum

Brand Name

Xiaflex

Dosage Form

Single-dose vial for injection

Drug Class

Miscellaneous uncategorized agents

Pharmacokinetics

Absorption:
Collagenase clostridium histolyticum, the active ingredient in Xiaflex, is administered by direct injection into affected tissues such as palmar cords in Dupuytren's contracture or penile plaques in Peyronie's disease. Due to this localized intratissue administration, systemic absorption of the enzyme is minimal and transient. The enzyme degrades local collagen fibrils, with limited systemic circulation. No significant oral absorption occurs since this drug is not administered orally. Clinical studies indicate that after injection, serum levels of collagenase components are low and decline rapidly, limiting systemic exposure.

Distribution:
Following localized injection, collagenase clostridium histolyticum remains primarily confined to the extracellular matrix in the targeted connective tissue. The enzyme shows high affinity for type I and III collagen within fibrotic cords or plaques. Minimal systemic distribution occurs owing to the local mode of administration and enzyme's rapid inactivation by circulating inhibitors. Distribution beyond the injection site is negligible, which limits systemic side effects but necessitates precise injection technique to avoid damage to adjacent structures such as nerves and tendons.

Metabolism:
Collagenase clostridium histolyticum is a bacterial protein mixture predominantly consisting of class I and class II collagenases. After injection, it enzymatically cleaves triple-helical collagen fibrils within pathological fibrotic tissue. Subsequently, the enzyme is inactivated and metabolized locally by proteolytic degradation and cellular uptake. Any enzyme that reaches systemic circulation is rapidly neutralized by protease inhibitors such as alpha-2-macroglobulin in plasma, which binds and inhibits the collagenase, leading to its clearance.

Elimination:
Systemically absorbed collagenase is primarily eliminated via proteolytic degradation and subsequent renal clearance of peptide fragments. Due to the rapid inactivation by plasma inhibitors, intact collagenase does not persist in circulation. The pharmacokinetic process ensures minimal systemic accumulation. No dose adjustments are typically required for renal or hepatic impairment. The localized enzymatic activity degrades pathological collagen without significant systemic elimination concerns.

Dosage Forms

Available Dosage Forms:
Xiaflex is supplied as a sterile, lyophilized powder in a single-dose vial containing 0.9 mg of collagenase clostridium histolyticum for injection. It is reconstituted with sterile water prior to administration. The formulation is intended exclusively for intralesional injection into affected fibrotic tissues.

Dosages for Adults and Adolescents:
For the treatment of Dupuytren's contracture, the recommended adult dose is 0.58 mg injected directly into a palpable cord causing contracture at a metacarpophalangeal (MP) or proximal interphalangeal (PIP) joint. Treatment may involve up to two cords or joints per hand per session, with a maximum of three treatment sessions per cord spaced approximately four weeks apart. A finger extension procedure is conducted 24 to 72 hours post-injection if contracture persists.

For Peyronie's disease, the adult dose is 0.58 mg injected into the palpable penile plaque once on two separate days, 1 to 3 days apart, constituting one treatment cycle. Up to four treatment cycles may be administered at six-week intervals based on clinical response, with modeling procedures and penile stretching exercises performed after injections.

Specific Patient Populations:
Safety and efficacy in pediatric populations have not been established; Xiaflex is indicated for adults only. There is insufficient data regarding use during pregnancy and lactation; caution is advised. No specific dosing adjustments are recommended for elderly patients or those with renal or hepatic impairment due to minimal systemic exposure. The drug should be administered by healthcare providers trained in injection techniques and management of potential adverse effects.

Mechanism Of Action

Collagenase clostridium histolyticum is a mixture of bacterial collagenases derived from Clostridium histolyticum that enzymatically degrade collagen types I and III, which are predominant components of fibrotic tissues such as Dupuytren's contracture cords and Peyronie's disease plaques. By cleaving the triple-helical collagen structure, the enzyme disrupts the pathological fibrosis that causes contracture and curvature.

Upon injection into affected tissues, collagenase selectively targets the abnormal collagen cords or plaques, resulting in enzymatic cleavage and weakening of the fibrotic tissue structure. This enzymatic digestion facilitates mechanical disruption and remodeling of the tissue, allowing improved mobility of joints in Dupuytren's contracture or reduction in penile curvature in Peyronie's disease.

At the cellular level, collagenase action leads to degradation of extracellular matrix components, impacting connective tissue remodeling pathways. The localized degradation triggers a controlled tissue response, promoting restoration of normal tissue elasticity. Importantly, the enzyme spares other matrix proteins and cells, focusing activity on collagen fibrils.

Clinically, this mechanism permits a minimally invasive approach to treat fibrotic contractures and plaques without extensive surgery. Comparative to other treatments, Xiaflex offers enzymatic tissue resolution with reduced morbidity and recovery time. Clinical studies demonstrate significant improvement in range of motion and deformity correction attributable to targeted collagen degradation, underpinning its therapeutic benefits.

Pharmacological Actions

Enzymatic cleavage of collagen type I and III in pathological fibrotic tissues.
Localized degradation of Dupuytren's contracture cords and Peyronie's plaques.
Reduction of contracture and curvature by disrupting dense collagen bundles.
Promotes connective tissue remodeling and restoration of joint and tissue function.
Selective action confined to abnormal collagen fibrils with minimal systemic activity.
Facilitates minimally invasive correction of fibrotic disorders.
Enables improved range of motion and functional outcomes in hand contractures.
Reduces penile curvature and deformity in Peyronie's disease through plaque breakdown.
Rapid enzyme inactivation by endogenous protease inhibitors limits systemic exposure.
Potential to cause local tissue damage if injected improperly near nerves or tendons.

Therapeutic Or Clinical Uses

Treatment of Dupuytren's contracture in adult patients with palpable cords.
Management of contractures associated with metacarpophalangeal (MP) and proximal interphalangeal (PIP) joints.
Treatment of Peyronie's disease in adult men with palpable penile plaques.
Reduction of finger contractures improving hand function and mobility.
Correction of abnormal penile curvature leading to improved sexual function.
Minimally invasive treatment alternative to surgery for fibrotic connective tissue disorders.
Improvement of range of motion in affected fingers post-treatment.
Facilitation of collagen degradation to enable mechanical extension procedures.
Adjunct therapy within a comprehensive management plan involving physical therapy and splinting.
Use under certified REMS program for Peyronie's disease to ensure safe administration.

Side Or Adverse Effects

Local injection site swelling, bruising, and pain.
Tenderness and redness at the injection site.
Swollen lymph nodes near the injection area (e.g., elbow or underarm).
Bruising or blistering of the skin at injection sites.
Numbness, tingling, or sensory disturbances in the treated finger or hand.
Increased pain or difficulty bending the injected finger after swelling subsides.
Tendon rupture or ligament injury in the treated hand due to enzymatic activity.
Allergic reactions including hives, facial swelling, and respiratory distress.
Bruising or swelling of the penis post-Peyronie's disease treatment.
Painful urination or hematuria after penile injection.
Sudden erectile dysfunction or penile popping sensation indicating possible tissue damage.
Systemic symptoms such as fever, chills, or signs of infection at injection site.
Potential risk of anaphylaxis requiring emergency intervention.
Skin discoloration and localized inflammation.
Back pain, chest pain, or neurological symptoms are rare but require immediate attention.

Precautions

Do not use if allergic to collagenase clostridium histolyticum or any component of Xiaflex.
Use caution in patients with bleeding or clotting disorders such as hemophilia.
Administer only by healthcare providers experienced in injection techniques and hand diseases.
Ensure patient enrollment and monitoring under the Xiaflex REMS program for Peyronie’s disease.
Avoid strenuous use of the treated hand until healing is sufficient to prevent tendon rupture.
Monitor vital signs and be prepared to manage severe allergic or local reactions.
Discontinue use and seek immediate care if signs of tendon rupture, severe pain, or nerve damage occur.
Pregnancy and breastfeeding: safety not established; weigh risks and benefits carefully.
Inform patients about potential for bruising, swelling, and functional impairment post-injection.
Patients should avoid sexual activity during and after treatment cycles for Peyronie’s disease as instructed.
Careful technique needed to avoid injection into nerves, blood vessels, or urethra in penile treatment.
Do not use for Peyronie's disease involving the urethra or with significant penile tissue damage.
Schedule appropriate follow-ups to assess response and complications.
Counsel patients on the gradual time course for clinical improvement, which may take weeks to months.

Warnings

Xiaflex can cause damage to nerves, tendons, or ligaments in the injected hand leading to functional impairment.
Immediate medical attention required if numbness, tingling, or inability to bend finger occurs post-injection.
Penile injections may cause damage to erectile tissue potentially necessitating corrective surgery.
Report bruising, swelling, pain when urinating, blood in urine, or sudden erection problems promptly.
Risk of severe allergic reactions including anaphylaxis necessitates availability of emergency care.
Avoid use in patients with bleeding or clotting disorders due to increased risk of bleeding complications.
Ensure patients understand activity restrictions post-injection to minimize risks of tissue injury.
Use under supervised protocols; improper administration increases risk of serious adverse events.
Monitor for signs of infection or systemic toxicity following injection.
Discontinue treatment and investigate immediately if unexpected systemic symptoms or severe pain arise.
Patients should be educated on signs requiring urgent medical evaluation, including sudden extension deficits.
Do not expose injection area to trauma or strain during initial recovery period to prevent complications.
Use cautiously in patients with multiple affected cords or joints due to increased procedural risk.
Manufacturer’s guidelines and local protocols must be strictly followed to mitigate risk.
Safety of multiple treatment courses in Peyronie’s disease beyond four cycles is not established.

Contraindication

Known hypersensitivity to collagenase clostridium histolyticum or formulation components.
Peyronie's disease affecting the urethra or with involvement of non-plaque penile tissue.
Patients with active infection at the injection site.
History of bleeding or blood clotting disorders such as hemophilia that increase bleeding risk.
Prior treatment with Xiaflex for another condition with unresolved adverse effects.
Use in pediatric populations due to lack of safety and efficacy data.
Use in pregnancy unless potential benefits outweigh risks due to unknown fetal effects.
Concurrent administration with other collagenase-containing products or proteolytic enzymes.
Severe hepatic or renal impairment not well studied; caution advised given unknown metabolism profiles.
Inability to comply with post-injection care requirements or REMS program stipulations.
Injection into tendons, nerves, blood vessels, or non-target tissues contraindicated due to risk of serious tissue damage.
Patients with uncooperative behavior or cognitive impairment posing increased procedural risk.
Known hypersensitivity to bacterial derived enzymes or related proteins.

Drug Interactions

Concomitant use with systemic anticoagulants (e.g., warfarin, Coumadin, Jantoven) may increase bleeding risk.
Other drugs that affect platelet function or coagulation may potentiate hemorrhagic complications.
No significant interactions reported with common over-the-counter medications; caution advised.
Potential interaction with protease inhibitors or enzyme modulators has not been well characterized.
Co-administration of other proteolytic enzymes could enhance local tissue degradation and adverse effects.
Monitoring is recommended if Xiaflex is used alongside medications impacting connective tissue integrity.
Caution with immunosuppressive therapies as it may alter healing and enzyme efficacy.
Herbal supplements affecting coagulation (e.g., ginkgo biloba, garlic) could increase bleeding risk when combined.
No known interactions with vitamins or minerals; however, systemic absorption is minimal.
Potential drug interactions with anesthetics or analgesics during injection procedures require clinical judgment.
Patients should disclose all prescription, OTC, and herbal medication usage prior to Xiaflex treatment.
No formal drug interaction studies conducted; clinical monitoring advised during concomitant therapy.
Avoid use with medications known to cause tendon toxicity due to cumulative tissue injury risk.

Preparations Of The Drug

Xiaflex is supplied as a sterile, lyophilized powder in a single-dose vial containing 0.9 mg collagenase clostridium histolyticum.
The drug is reconstituted with sterile water for injection immediately prior to administration.
Formulation is designed specifically for intralesional injection into fibrotic cords or plaques.
Packaging includes a vial, diluent vial, and appropriate instructions for safe preparation.
Supplied under restricted distribution programs, especially for Peyronie’s disease (Xiaflex REMS).
Requires storage under refrigerated conditions (2°C to 8°C) and protection from light.
Not intended for intravenous, intramuscular, or subcutaneous administration.
Manufactured by Auxilium Pharmaceuticals, Inc., with quality control ensuring purity of the collagenase enzymes.
Biosimilar products such as Qwo are available with differing vial strengths (0.92 mg and 1.84 mg).
Preparation must ensure sterility and accurate dosing to avoid complications.
Used only in healthcare settings with trained professionals to prevent administration errors.
Accompanying materials may include labeling for appropriate handling of potential allergic reactions.
Disposal of unused product must comply with biohazard regulations.
Instructions emphasize avoidance of contamination and rapid use after reconstitution.
Preparation and handling protocols include monitoring to minimize risks of dose variability.